Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Convertible Debt (2019 - 2025)

Cytokinetics (CYTK) has disclosed Convertible Debt for 7 consecutive years, with $889.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Convertible Debt rose 61.3% to $889.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $889.5 million, a 61.3% increase, with the full-year FY2023 number at $549.0 million, up 0.58% from a year prior.
  • Convertible Debt was $889.5 million for Q3 2025 at Cytokinetics, up from $554.0 million in the prior quarter.
  • In the past five years, Convertible Debt ranged from a high of $889.5 million in Q3 2025 to a low of $90.9 million in Q1 2021.
  • A 5-year average of $420.7 million and a median of $546.9 million in 2023 define the central range for Convertible Debt.
  • Peak YoY movement for Convertible Debt: surged 480.48% in 2022, then increased 0.58% in 2023.
  • Cytokinetics' Convertible Debt stood at $95.5 million in 2021, then skyrocketed by 471.7% to $545.8 million in 2022, then grew by 0.58% to $549.0 million in 2023, then rose by 0.45% to $551.5 million in 2024, then soared by 61.3% to $889.5 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Convertible Debt are $889.5 million (Q3 2025), $554.0 million (Q2 2025), and $553.1 million (Q1 2025).